Latest Period
Q2 2026
Security Snapshot
BriaCell Therapeutics Corp. - Common Shares, no par value per share (the "Shares") (BCTX) Institutional Ownership
CUSIP: 107930307
13F Institutional Holders and Ownership History from Q3 2025 to Q2 2026
Institutions Reporting
17
Shares (Excl. Options)
486,102
Price
$3.24
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value per share (the "Shares")
- Symbol
- BCTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 486,102
- Total 13F value
- $1,574,828
- Portfolio coverage rank
- 0%
- Share change
- +99,398
- Value change
- +$321,936
- Number of holders
- 17
- Shares outstanding
- 7,179,159
- SEC-reported price per share
- $3.63
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BCTX - BriaCell Therapeutics Corp. - Common Shares, no par value per share (the "Shares") is tracked under CUSIP 107930307.
- 17 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 14 to 17 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,619,329 to $1,574,828.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 17 institutions filings for Q2 2026.
Security key
107930307
Latest holder period
Q2 2026
13F holders
17
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
BCTX full holder history
BriaCell Therapeutics Corp. SEC filings
BriaCell Therapeutics Corp. company facts
BriaCell Therapeutics Corp. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 107930307:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
BCTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 10% | $5,119,574 | 717,198 | Kenneth Griffin | 15 Jan 2026 | |||
| CVI Investments, Inc. | 4.9% | $1,088,384 | 98,944 | CVI Investments, Inc. | 30 Sep 2025 | |||
| Iroquois Capital Management, LLC | 5% | $1,088,384 | 98,944 | Richard Abbe | 30 Sep 2025 |
As of 30 Jun 2026, 17 institutional investors reported holding 486,102 shares of BriaCell Therapeutics Corp. - Common Shares, no par value per share (the "Shares") (BCTX). This represents 6.8% of the company’s total 7,179,159 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Latest
Q2 2026
Rows shown
1-4 of 4